<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03729804</url>
  </required_header>
  <id_info>
    <org_study_id>IRB18-1243</org_study_id>
    <nct_id>NCT03729804</nct_id>
  </id_info>
  <brief_title>Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)</brief_title>
  <acronym>(COBRA)</acronym>
  <official_title>A Randomized, Open-label Phase 3 Study of Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized multicenter study that will compare two treatment regimens (Kyprolis,&#xD;
      Revlimid, dexamethasone -KRD vs. Velcade, Revlimid, dexamethasone -VRD) for patients with&#xD;
      newly diagnosed multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">December 24, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 24, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with progression free survival with the group taking KRd versus VRd after randomization</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of MRD-negative (minimal residual disease) at indicated time points of study after randomization</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The combination of drugs (KRd vs VRd) with the best response using minimal residual disease analysis across entire treatment in high risk and low risk patients</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The combination of drugs (KRd vs VRd) safety and tolerability based on patients response</measure>
    <time_frame>5 years</time_frame>
    <description>The safety and tolerability of lenalidomide and carfilzomib will be evaluated by means of drug related Adverse Events reports.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the correlation between treatment outcome using KRd or VRd and pre-treatment</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>KRD Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to this group will receive a combination of carfilzomib, lenalidomide, and dexamethasone in 28 day cycles. Doses will vary</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VRD Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to this group will receive a combination of Bortezomib, lenalidomide and dexamethasone in 21-day cycles. Doses will vary</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Carfilzomib will be given by IV on Days 1, 2, 15 and 16 of each cycle during cycles 1-8.&#xD;
Carfilzomib will be given by IV on days 1, 2, 15 and 16 of each cycle during cycles 9-24.</description>
    <arm_group_label>KRD Arm</arm_group_label>
    <other_name>Kyprolis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Lenalidomide will be taken by mouth once a day for days 1-21 of each cycle during cycles 1-8.&#xD;
Lenalidomide will be taken by mouth once a day for days 1-21 of each cycle for cycles 9-24.</description>
    <arm_group_label>KRD Arm</arm_group_label>
    <arm_group_label>VRD Arm</arm_group_label>
    <other_name>CC-5013</other_name>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone will be taken by mouth on days 1, 8, 15 and 22 of each cycle during cycles 1-8.&#xD;
Dexamethasone will be taken by mouth on Days 1, 8, 15 and 22 of each cycle during cycles 9-24.</description>
    <arm_group_label>KRD Arm</arm_group_label>
    <arm_group_label>VRD Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Bortezomib will be give by IV on days 1, 4, 8 and 11 of each cycle during cycles 1-8.</description>
    <arm_group_label>VRD Arm</arm_group_label>
    <other_name>Velcade</other_name>
    <other_name>PS-341</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Newly diagnosed, previously untreated myeloma requiring systemic chemotherapy per&#xD;
             International Myeloma Working Group criteria:&#xD;
&#xD;
             • Patients must have received no prior chemotherapy for this disease; patients must&#xD;
             have received no prior radiotherapy to a large area of the pelvis (more than half of&#xD;
             the pelvis); prior steroid treatment is allowed provided treatment was not more than 2&#xD;
             weeks in duration and less than or equal to 160 mg dexamethasone; patients must not&#xD;
             have received any prior treatment with bortezomib or lenalidomide&#xD;
&#xD;
          2. Both transplant and non-transplant candidates are eligible. Transplant candidates must&#xD;
             agree to defer transplant at time of consent.&#xD;
&#xD;
          3. Diagnosis of symptomatic multiple myeloma as per current International Myeloma Working&#xD;
             Group uniform criteria prior to initial treatment&#xD;
&#xD;
          4. Monoclonal plasma cells in the BM 10% or presence of a biopsy-proven plasmacytoma&#xD;
&#xD;
          5. Measurable disease, prior to initial treatment as indicated by one or more of the&#xD;
             following:&#xD;
&#xD;
               -  Serum M-protein greater than or equal to 1 g/dL&#xD;
&#xD;
               -  Urine M-protein greater than or equal to 200 mg/24 hours&#xD;
&#xD;
               -  If serum protein electrophoresis is felt to be unreliable for routine M-protein&#xD;
                  measurement, then quantitative immunoglobulin levels are acceptable&#xD;
&#xD;
          6. Bone marrow specimen will be required at study entry; available DNA sample from&#xD;
             pre-induction BM will be used for calibration step for Minimal Residual Disease&#xD;
             evaluation by gene sequencing.&#xD;
&#xD;
          7. Males and females 18 years of age or older.&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group performance status of 0-1&#xD;
&#xD;
          9. Adequate hepatic function, with bilirubin less than or equal to 1.5 x ULN and aspirate&#xD;
             aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x&#xD;
             ULN&#xD;
&#xD;
         10. ANC greater than or equal to 1.0 x 109/L, hemoglobin greater than or equal to 8 g/dL,&#xD;
             platelet count greater than or equal to 75 x 109/L.&#xD;
&#xD;
         11. Calculated creatinine clearance (by Cockroft-Gault) greater than or equal to 50 mL/min&#xD;
             or serum creatinine below 2 g/dL&#xD;
&#xD;
         12. FCBP must have 2 negative pregnancy tests (sensitivity of at least 50 mIU/mL) prior to&#xD;
             initiating lenalidomide. The first pregnancy test must be performed within 10-14 days&#xD;
             before and the second pregnancy test must be performed within 24 hours before&#xD;
             lenalidomide is prescribed for Cycle 1 (prescriptions must be filled within 7 days).&#xD;
&#xD;
         13. FCBP must agree to use 2 reliable forms of contraception simultaneously or to practice&#xD;
             complete abstinence from heterosexual intercourse during the following time periods&#xD;
             related to this study: 1) for at least 28 days before starting lenalidomide; 2) while&#xD;
             participating in the study; and 3) for at least 30 days after discontinuation from the&#xD;
             study.&#xD;
&#xD;
         14. Male subjects must agree to use a latex condom during sexual contact with females of&#xD;
             childbearing potential while participating in the study and for at least 90 days&#xD;
             following discontinuation from the study even if he has undergone a successful&#xD;
             vasectomy.&#xD;
&#xD;
         15. All study participants in the US must be consented to and registered into the&#xD;
             mandatory Revlimid REMS® program and be willing and able to comply with the&#xD;
             requirements of Revlimid REMS®.&#xD;
&#xD;
         16. Subjects must comply with pregnancy prevention and counseling&#xD;
&#xD;
         17. Voluntary written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients meeting any of the following exclusion criteria are not eligible to enroll in this&#xD;
        study.&#xD;
&#xD;
          1. Frail non-transplant candidates, defined as in Palumbo et al, Blood 2015&#xD;
&#xD;
          2. Non-secretory or hyposecretory multiple myeloma, prior to initial treatment defined as&#xD;
             less than 1.0 g/dL M-protein in serum, less than 200 mg/24 hr urine M-protein&#xD;
&#xD;
          3. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and&#xD;
             skin changes)&#xD;
&#xD;
          4. Amyloidosis&#xD;
&#xD;
          5. Plasma cell leukemia&#xD;
&#xD;
          6. Waldenström's macroglobulinemia or IgM myeloma&#xD;
&#xD;
          7. Radiotherapy to multiple sites or immunotherapy within 4 weeks before start of&#xD;
             protocol treatment (localized radiotherapy to a single site at least 1 week before&#xD;
             start is permissible)&#xD;
&#xD;
          8. Participation in an investigational therapeutic study within 3 weeks or within 5 drug&#xD;
             half-lives (t1/2) prior to first dose, whichever time is greater&#xD;
&#xD;
          9. Potential subjects with evidence of progressive disease as per IMWG criteria&#xD;
&#xD;
         10. Patients not able to tolerate daratumumab, carfilzomib, lenalidomide or dexamethasone&#xD;
&#xD;
         11. Peripheral neuropathy greater than or equal to Grade 2 at screening&#xD;
&#xD;
         12. Diarrhea greater than Grade 1 in the absence of antidiarrheals&#xD;
&#xD;
         13. CNS involvement&#xD;
&#xD;
         14. Patients who cannot undergo or unwilling to take thromoprophylaxis&#xD;
&#xD;
         15. Uncontrolled or symptomatic angina, arrhythmia, hypertension, CHF, EF less than 40%,&#xD;
             within 6 months prior to first dose&#xD;
&#xD;
         16. Pregnant or lactating females&#xD;
&#xD;
         17. Major surgery within 3 weeks prior to first dose.&#xD;
&#xD;
         18. Myocardial infarction within 6 months prior to enrollment, NYHA Class III or IV heart&#xD;
             failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or&#xD;
             electrocardiographic evidence of acute ischemia or active conduction system&#xD;
             abnormalities&#xD;
&#xD;
         19. Prior or concurrent pulmonary embolism&#xD;
&#xD;
         20. Known moderate or severe persistent asthma or known chronic obstructive pulmonary&#xD;
             disease (COPD)&#xD;
&#xD;
         21. Rate-corrected QT interval of electrocardiograph (QTc) greater than 470 msec on a&#xD;
             12-lead ECG during screening&#xD;
&#xD;
         22. Uncontrolled diabetes&#xD;
&#xD;
         23. Acute infection requiring systemic antibiotics, antivirals, or antifungals within two&#xD;
             weeks prior to first dose&#xD;
&#xD;
         24. Known seropositive for or active viral infection with human immunodeficiency virus&#xD;
             (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are&#xD;
             seropositive because of hepatitis B virus vaccine are eligible.&#xD;
&#xD;
         25. Non-hematologic malignancy or non-myeloma hematologic malignancy within the past 3&#xD;
             years except a) adequately treated basal cell, squamous cell skin cancer, thyroid&#xD;
             cancer, carcinoma in situ of the cervix, or prostate cancer less than Gleason Grade 6&#xD;
             with stable prostate specific antigen levels or cancer considered cured by surgical&#xD;
             resection alone&#xD;
&#xD;
         26. Any clinically significant medical disease or condition that, in the Investigator's&#xD;
             opinion, may interfere with protocol adherence or a subject's ability to give informed&#xD;
             consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrzej Jakubowiak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrzej Jakubowiak</last_name>
    <phone>(773) 834-1592</phone>
    <email>ajakubowiak@medicine.bsd.uchicago.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Of Chicago Medicine Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Intake</last_name>
      <phone>855-702-8222</phone>
      <email>cancerclinicaltrials@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Andrzej Jakubowiak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 12, 2018</study_first_submitted>
  <study_first_submitted_qc>October 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2018</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

